The evolving management for Peyronie's disease has sparked debates, especially since the Food and Drug Administration approval of collagenase Clostridium histolyticum (CCH) as a treatment option. Green et al (page 791) from Orem, Utah, add some clarity after conducting this randomized trial to compare the efficacy of CCH vs penile surgery (with the addition of a penile traction therapy device and sildenafil in both groups). 1 The results showed that the men undergoing CCH treatment reported higher satisfaction rates (50% vs 21%) and better subjective erectile function, penile length, and penile sensation. Not surprisingly, the surgery group experienced greater improvements in curvature but higher rates of adverse events. The authors suggest that, at least at the 3-month mark, CCH treatment leads to favorable outcomes in terms of subjective erectile function, penile length, and adverse events when compared to surgical intervention for Peyronie's disease.